skip to Main Content

Dr. Chung on the COMPASS Trial in Pancreatic Cancer

Dr. Chung on the COMPASS Trial in Pancreatic Cancer
Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, director of the Phase I Program, City of Hope, discusses the COMPASS trial in pancreatic cancer.

The most exciting trial that came out of the 2019 Gastrointestinal Cancer Symposium was the COMPASS trial, says Chung. COMPASS was a prospective trial that was conducted in Canada in which patients who were undergoing frontline therapy underwent concurrent tumor tissue biopsy and sequencing. Investigators did RNA sequencing as well as patient-derived organoids, results of which were received an average of 39 days later, says Chung. Watch here . . .


Back To Top